Castillo-Bejarano JI, Guerrero-Márquez NA, Vaquera-Aparicio DN, Mascareñas-de los Santos AH, Cárdenas-del Castillo BG, Garza-Bulnes R

Idioma: Español
Referencias bibliográficas: 15
Paginas: 138-142
Archivo PDF: 195.23 Kb.

RESUMEN

La tuberculosis resistente es un problema de salud pública mundial. Aunque la resistencia a isoniazida tiene una prevalencia de 5.7% en la región de las Américas, la información disponible sobre el manejo de estos casos en niños es escasa, por lo que la elección del esquema y la duración del tratamiento es un dilema. Describimos un caso con diagnóstico tardío de monorresistencia a isoniazida y una revisión de la literatura.

REFERENCIAS (EN ESTE ARTÍCULO)

1. World Health Organization. Global Tuberculosis Report 2019. Geneva, Switzerland: World Health Organization; 2019.

2. Gegia M, Winters N, Benedetti A, van Soolingen D, Menzies D. Treatment of isoniazid-resistant tuberculosis with first-line drugs: a systematic review and meta-analysis. Lancet Infect Dis. 2017; 17 (2): 223-234.

3. Stagg HR, Harris RJ, Hatherell HA et al. What are the most efficacious treatment regimens for isoniazid-resistant tuberculosis? A systematic review and network meta-analysis. Thorax. 2016; 71 (10): 940-949.

4. World Health Organization. WHO treatment guidelines for isoniazid-resistant tuberculosis: supplement to the WHO treatment guidelines for drug-resistant tuberculosis. Geneva, Switzerland: World Health Organization; 2018.

5. World Health Organization. WHO consolidated guidelines on drug-resistant tuberculosis treatment. Geneva, Switzerland: World Health Organization; 2019.

6. Jenkins HE, Yuen CM. The burden of multidrug-resistant tuberculosis in children. Int J Tuberc Lung Dis. 2018; 22 (5): S3-S6.

7. Dodd PJ, Sismanidis C, Seddon JA. Global burden of drug resistant tuberculosis in children: a mathematical modelling study. Lancet Infect Dis. 2016; 16 (10): 1193-1201.

8. Yuen CM, Tolman AW, Cohen T, Parr JB, Keshavjee S, Becerra MC. Isoniazid-resistant tuberculosis in children: a systematic review. Pediatr Infect Dis J. 2013; 32 (5): e217-e226.

9. Yuen CM, Jenkins HE, Rodriguez CA, Keshavjee S, Becerra MC. Global and regional burden of isoniazid-resistant tuberculosis. Pediatrics. 2015; 136 (1): e50-e59.

10. World Health Organization. Guidance for national tuberculosis programs on the management of tuberculosis in children. 2nd ed. Geneva, Switzerland: World Health Organization; 2014.

11. Bollela VR, Namburete EI, Feliciano CS, Macheque D, Harrison LH, Caminero JA. Detection of katG and inhA mutations to guide isoniazid and ethionamide use for drug-resistant tuberculosis. Int J Tuberc Lung Dis. 2016; 20:1099-1104.

12. Abate D, Tedla Y, Meressa D, Ameni G. Isoniazid and rifampicin resistance mutations and their effect on second-line anti-tuberculosis treatment. Int J Tuber Lung Dis. 2014; 18 (8): 946-951.

13. Vadwai V, Boehme C, Nabeta P, Shetty A, Alland D, Rodrigues C. Xpert MTB/RIF: a new pillar in diagnosis of extrapulmonary tuberculosis? J Clin Microbiol. 2011; 49 (7): 2540-2545.

14. Bates M. The development, evaluation and performance of molecular diagnostics for detection of Mycobacterium tuberculosis. Expert Rev Mol Diagn. 2016; 16 (3): 307-322.

15. Fregonese F, Ahuja SD, Akkerman OW et al. Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis. Lancet Respir Med. 2018; 6 (4): 265-275.